A cikin wata hira da aka yi kwanan nan, Dokta Afsaneh Barzi, mataimakin farfesa na likitancin asibiti a Jami'ar Southern California Norris Comprehensive Cancer Center, ya gaya muku game da data kasance da kuma bullowar sabbin hanyoyin kwantar da hankali ga marasa lafiya da ciwon daji na pancreatic ba na metastatic ba.
An ba Gemcitabine ga marasa lafiya da ke fama da cutar sankara a matsayin mizanin aiki don tantance martani. Koyaya, Barzi ya ce amsar mara lafiyar ga gemcitabine ba ta da kyau sosai kuma yawancin marasa lafiya ba sa iya yin tiyata. Gwajin LAPACT ya binciki maganin haɗin gemcitabine da nab-paclitaxel (Abraxane). Gwaje-gwaje sun nuna cewa kashi 36% na masu cutar sankarau suna amsar magani, kuma kusan kashi 15% na masu cutar kansa na iya karɓar magani.
Bugu da kari, wani bincike-bincike na binciken FOLFIRINOX na marasa lafiya da ke fama da ciwon daji na pancreatic a cikin gida ya nuna cewa kusan kashi 28% na masu ciwon daji na pancreatic sun sami damar yin tiyata. Barzi ya bayyana cewa, yayin da cutar sankarau ke ƙara yin tasiri, yuwuwar kamuwa da cutar tana ƙaruwa. Saboda haka, ya kamata a yi la'akari da resection na haƙuri daidai. Barzi ya kammala da cewa, kodayake yawancin marasa lafiya na iya zama ba su cancanci yin tiyata ba, har yanzu yana da daraja a kimanta marasa lafiya don nemo majinyata da za su iya yin aikin tiyata bayan maganin neoadjuvant.
